ℹ️ Compiled from public regulatory records · Last regulator revision: February 16, 2023🚩 Report this page
Mobocertinib
Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors
Sold as EXKIVITY
GB MHRA
- Drug class
- Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors
- Availability
- See label
- Markets covered
- 1
- Products on record
- 1
Overview
Mobocertinib is an active pharmaceutical ingredient in the Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors group (L01EB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | February 16, 2023 |
GBUnited Kingdom· MHRA
1 product
Sources & citations
- [1]MHRA (UK) · PLGB161890124 · revised February 16, 2023
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.